The present invention provides a film coated tablet comprising a first film coating layer comprising hydroxypropyl methylcellulose and a second film coating layer comprising polyvinyl alcohol, on a tablet containing choline alfoscerate as an active ingredient and magnesium aluminometasilicate as an additive; and a process for preparing the same.

This application relates to the modulation of the flora of bacteria in an environment by inhibiting the quorum sensing of a specific bacteria in said environment by administering an effective amount of a quorum sensing control composition comprising at least one quorum sensing control agent, which is an adsorbent/catalytic inhibitor for a QS signal molecule, such as, N-acyl homoserine lactones (AHL), pseudomonas quinolone signal (PQS), and autoinducer-1 (AI-1), autoinducer-2 (AI-2) type of quorum sensing molecules. Quorum sensing control agents include a sorbent material, sorbent mineral or non-porous mineral such as, for example, phyllosilicate clays, silica, calcite, zeolites, diatomaceous earth, smectite, activated carbon, a nanoparticle or a combination of any of the foregoing. Methods include inhibiting the spoilage of food stuffs and preventing vibriosis in fish or shell fish.

This application relates to the modulation of the flora of bacteria in an environment by inhibiting the quorum sensing of a specific bacteria in said environment by administering an effective amount of a quorum sensing control composition comprising at least one quorum sensing control agent, which is an adsorbent/catalytic inhibitor for a QS signal molecule, such as, N-acyl homoserine lactones (AHL), pseudomonas quinolone signal (PQS), and autoinducer-1 (AI-1), autoinducer-2 (AI-2) type of quorum sensing molecules. Quorum sensing control agents include a sorbent material, sorbent mineral or non-porous mineral such as, for example, phyllosilicate clays, silica, calcite, zeolites, diatomaceous earth, smectite, activated carbon, a nanoparticle or a combination of any of the foregoing. Methods include inhibiting the spoilage of food stuffs and preventing vibriosis in fish or shell fish.

Kits, compositions and methods are provided which comprise a nutritional composition and an adjuvant composition. The nutritional composition comprises vitamin A, vitamin C, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9, vitamin B12, iron, iodine, magnesium, zinc, copper, a source of omega-3 fatty acids and one or more pharmaceutically-acceptable carriers. The adjuvant composition is formulated to mitigate at least one undesired side effect associated with the administering of the first composition to the patient. The first composition may comprise at least about 90 mg of iron. The iron may be provided in the form of a polysaccharide iron complex. The adjuvant composition may comprise fiber or a laxative to mitigate the undesired side effects of the relatively high iron content of the nutritional composition.

Kits, compositions and methods are provided which comprise a nutritional composition and an adjuvant composition. The nutritional composition comprises vitamin A, vitamin C, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B9, vitamin B12, iron, iodine, magnesium, zinc, copper, a source of omega-3 fatty acids and one or more pharmaceutically-acceptable carriers. The adjuvant composition is formulated to mitigate at least one undesired side effect associated with the administering of the first composition to the patient. The first composition may comprise at least about 90 mg of iron. The iron may be provided in the form of a polysaccharide iron complex. The adjuvant composition may comprise fiber or a laxative to mitigate the undesired side effects of the relatively high iron content of the nutritional composition.

It discloses an iron-based montmorillonite medicine for treating hyperphosphatemia and iron deficiency anaemia, and the preparation method thereof. The medicine comprises effective ingredient iron-based montmorillonite (Fe-montmorillonite) which is obtained by soaking or eluting the medicinal montmorillonite by water soluble iron salt solution. The effective ingredient is added by pharmaceutic adjuvant or not to make medicanent which is given via gastrointestinal tract. The effective ingredient binds the phosphate in the patients' digestive tract to form insoluble matter which can be excreted from the body via the digestive tract, therefore the phosphate in the patients with chronic renal failure is reduced and the goal of treating hyperphosphatemia is achieved.

It discloses an iron-based montmorillonite medicine for treating hyperphosphatemia and iron deficiency anaemia, and the preparation method thereof. The medicine comprises effective ingredient iron-based montmorillonite (Fe-montmorillonite) which is obtained by soaking or eluting the medicinal montmorillonite by water soluble iron salt solution. The effective ingredient is added by pharmaceutic adjuvant or not to make medicanent which is given via gastrointestinal tract. The effective ingredient binds the phosphate in the patients' digestive tract to form insoluble matter which can be excreted from the body via the digestive tract, therefore the phosphate in the patients with chronic renal failure is reduced and the goal of treating hyperphosphatemia is achieved.

It discloses an iron-based montmorillonite medicine for treating hyperphosphatemia and iron deficiency anaemia, and the preparation method thereof. The medicine comprises effective ingredient iron-based montmorillonite (Fe-montmorillonite) which is obtained by soaking or eluting the medicinal montmorillonite by water soluble iron salt solution. The effective ingredient is added by pharmaceutic adjuvant or not to make medicanent which is given via gastrointestinal tract. The effective ingredient binds the phosphate in the patients' digestive tract to form insoluble matter which can be excreted from the body via the digestive tract, therefore the phosphate in the patients with chronic renal failure is reduced and the goal of treating hyperphosphatemia is achieved.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.

The present invention is directed to methods for treating or ameliorating skin conditions, diabetic conditions, cardiovascular conditions, cancer, infections or metal poisoning, enhancing performance, or providing nutritional support, comprising administering to a subject in need thereof compositions comprising a magnetic dipole stabilized solution (MDSS). The MDSS solution may include additional components and can be provided in a kit.